




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 211/34, 213/54, 213/73, A61K 31/44, 31/445	A1	(11) International Publication Number: WO 00/66557 (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/SE00/00834 (22) International Filing Date: 3 May 2000 (03.05.00) (30) Priority Data: 9901573-7 3 May 1999 (03.05.99) SE (71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (73) Inventors/Applicants (for US only): LINSCHOTEN, Marcel [NL/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). POLLA, Magnus [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SVENSSON, Peder [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). (74) Agent: ASTRAZENECA AB; Global Intellectual Property, Patents, S-151 85 Södertälje (SE).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NEW COMPOUNDS  $\begin{array}{c} R1 \\ \\ X - C - R2 \\ \quad \diagup \\ Y \quad R3 \\ \\ R4 \end{array}$ (I) (57) Abstract The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.		